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Objective: To characterize deﬁcits in burrowing behavior e an ethologically-relevant rodent behavior e
in the monosodium iodoacetate (MIA) rat model of osteoarthritis (OA), and the sensitivity of these
deﬁcits to reversal by analgesic drugs of both prototypical and novel mechanisms of action. A second
objective was to compare the burrowing assay to a spontaneous locomotor activity (sLA) assay.
Method: Male Wistar Han rats (200e220 g) received intrarticular (i.a.) injections of MIA or saline for
sham animals. A deﬁcit in the amount of sand burrowed from steel tubes ﬁlled with 2.5 kg of sand was
used as a measure of pain-related behavior, and sensitivity to reversal of these deﬁcits by analgesic drugs
was assessed in bilaterally MIA-injected rats.
Results: Bilateral MIA injections induced a signiﬁcant impairment of burrowing behavior, which was
concentration-dependent. The temporal pattern of the deﬁcits was biphasic: a large deﬁcit at 3 days
post-injection, resolving by day 14 and returning at the 21 and 28 day time points. At the 3 day time
point ibuprofen, celecoxib and an anti-nerve growth factor (NGF) monoclonal antibody (mAb) were able
to signiﬁcantly reinstate burrowing behavior, whereas the fatty acid amide hydrolase (FAAH) inhibitor
PF-04457845 and morphine displayed no reversal effect. Morphine impaired burrowing behavior at
3 mg/kg in sham animals. Deﬁcits in rearing frequency in the locomotor activity assay proved irreversible
by analgesics.
Conclusion: Burrowing behavior provides an objective, non-reﬂexive read-out for pain-related behavior
in the MIA model that has predictive validity in detecting analgesic efﬁcacy of nonsteroidal anti-
inﬂammatory drugs (NSAIDs) and an anti-NGF mAb.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The prevalence of osteoarthritis (OA) is estimated to be 50% in
people aged 65 and older1 and with an aging population the cost
and health impact of this disease will continue to rise. The intra-
articular (i.a.) injection of monosodium iodoacetate (MIA) into
the rat knee joint produces histological changes representative of
those seen in human OA2. Concomitant with the early and lateA. Pekcec, Boehringer Ingel-
any, Birkendorfer Strasse 65,
54-92312; Fax: 49-7351-54-
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ternational. Published by Elsevier Lhistological changes in the MIA model are pain-related behaviors3,
making it a useful model for assessing the analgesic efﬁcacy of
drugs.
Pain is the main clinical manifestation of OA. The current lack of
effective disease modifying agents to target the aetiology of OA4
means the use of analgesic drugs is the mainstay treatment for
alleviating the impact of the disease on daily life, namely non-
steroidal anti-inﬂammatory drugs (NSAIDs) and weak opioids5.
The main techniques for assessing pain-like behaviors in the
MIA model are measures of mechanical hypersensitivity: shifts in
weight bearing (WB) from the ipsilateral affected to contralateral
unaffected knee, distal mechanical hyperalgesia and tactile
allodynia6e8. A pressing issue in the pain ﬁeld is the lack of trans-
lation between preclinical and clinical ﬁndings, which has resulted
in relatively few safe and effective analgesics being developed
(reviewed by Blackburn-Munro 20049 and Mogil, 200910).td. All rights reserved.
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predictive validity from rat to human11, it is becoming increasingly
apparent that assays utilizing spontaneous rather than evoked/re-
ﬂexive measures are needed to assess the global impact of pain
beyond hypersensitivity12,13.
In addition to sharp pain evoked bymovement, patients with OA
rank constant and aching pain among the most distressing features
of the disease14. How well the current evoked/reﬂexive assays of
pain-like behaviors in rodents account for this persistent pain is
unclear9. Furthermore, clinical assessments of chronic pain are
focusing increasingly on the multifaceted nature of pain, such as
the effect on emotion and physical function15, which are not
assessed preclinically by reﬂexive assays.
Burrowing is an innate rodentbehavior indicative of animalwell-
being that is conserved across various strains of rat16e19 and
mice20e22. Deﬁcits in burrowing behavior occur in preclinical rat
models of inﬂammatory and neuropathic pain and can be reversed
by analgesics16,18,19,23,24. This behavior, therefore, is a useful pre-
clinicalmeasureof non-evokedpain. Burrowingmayencompass the
supraspinal mechanisms that contribute to pain phenotypes, both
sensory and affective, as well as being more ethologically relevant
than the commonly used assays measuring hypersensitivity25.
Here we show deﬁcits in burrowing behavior in the bilateral
MIA model of OA and sensitivity of these deﬁcits to reversal by
prototypical and novel analgesics. To our knowledge, this is the ﬁrst
published article demonstrating deﬁcits in burrowing behavior in
the MIA model. Additionally, burrowing behavior was compared to
another non-reﬂexive readout: spontaneous locomotor activity
(sLA). This has been shown previously to be impaired in various
preclinical animal models and to be sensitive to pharmacological
modulation26e29.
Methods
Animals
594 male Wistar Han rats (200e220 g; Charles River Labora-
tories, Germany) were used for all experiments and were housed in
groups of four with food and water ad libitumwith a 12 h light/dark
cycle. All animal experimental protocols were authorized by the
Local Animal Care and Use Committee and carried out according to
the local animal care guidelines, AAALAC regulations, and the USDA
Animal Welfare Act.
MIA injections
Rats were brieﬂy anaesthetized with 5% isoﬂurane (Abbott Lab-
oratories, Wiesbaden, Germany) followed by 3% maintenance, after
which an i.a. injection of 3 mg of MIA (SigmaeAldrich, Steinheim,
Germany) dissolved in 50 mL of 0.9% physiological saline was per-
formed into the femorotibial joint. Sham rats received 50 mL in-
jections of physiological saline. All injections for pharmacology
experimentswere bilateral, except for onemodel conditions studies
in which rats received either uni- or bilateral injections.
Drugs and drug administration
The analgesic drugs tested were: morphine (Caelo, Germany),
ibuprofen (Sigma Aldrich, Steinheim, Germany), celecoxib (LKT
Laboratories Inc., St. Paul, MN, USA) and the fatty acid amide
hydrolase (FAAH) inhibitor PF-04457845 (synthesized by Boeh-
ringer Ingelheim). All drugs were administered orally (p.o.) with
0.5% (w/v) natrosol and 0.1% (v/v) tween-80 (9:1 ratio) as vehicle,
except morphine which was injected subcutaneously (s.c.) in the
interscapular area with 0.9% physiological saline as vehicle. Alldrugs were administered in a volume of 2 mL/kg except PF-
04457845, which was administered in a volume of 4 mL/kg.
For the generation of the anti-nerve growth factor (NGF),
monoclonal antibody (mAb) variable domains were extracted from
the patent application WO 2004/058184 A2 (applicant: Rinat
Neuroscience Corporation) and processed as described by Hezareh
et al., 200130. The antibody was administered s.c., with phosphate
buffered saline as vehicle.
Burrowing training and burrowing experiments
For all burrowing experiments steel tubes (32 cm in length and
10 cm in diameter) were ﬁlled with 2.5 kg of quartz sand and placed
in Plexiglas cages (600 340 200mm). The open-end of the tube
was elevated 6 cm from the ﬂoor of the cage. Training for each
experiment was carried in 2 phases: social facilitation (SF) and
individual training (IT). For SF rats were placed in pairs in a cage for
2 h on two consecutive days. The amount of sand burrowed by each
pair was measured and if a pair burrowed less than 1500 g of sand
one of the pair was swapped with a rat from a pair that had bur-
rowed greater than 1500 g for the second SF day. For IT rats were
placed alone in the burrowing set-up for 30 min per day and the
average amount burrowed over 3 days was calculated to attain a
baseline burrowing performance value.
Before each animal was given MIA or sham intrarticular in-
jections theywere assigned to groups to ensure that each treatment
group for an experiment had a comparable baseline burrowing
value. For the model conditions study rats were allowed to indi-
vidually burrow for 30 min 3 days after MIA or sham injections
were performed and the amount of sand burrowed was recorded.
For the time-course experiment burrowing performance was
assessed 3, 14, 21 and 28 days post-injection. For all pharmacology
experiments burrowing behavior was measured 3 days after MIA
injection, and animals were placed in the burrowing set-up after
the appropriate pre-treatment time.
Exclusions
During training any animal that has a baseline burrowing value of
less than 1000 g or a standard deviation of burrowing (SD) greater
than450gwasexcludedtoensurehighandstablebaselines.Toensure
that all rats used inpharmacology experiments were in a comparable
pain state burrowing values were also measured 1 day after MIA in-
jection and any animal with a burrowing value greater than 1000 g
was excluded from pharmacology at day 3. In total, exclusions after
training and after day 1 accounted for around 5% of rats per study.
Locomotor activity
sLA was measured for 30 min with an automated monitoring
system (TruScan Activity Monitor version 2.0, Coulbourn In-
struments, Allentown, PA, USA). Each monitoring system was an
enclosed 43 cm2 arenawith two levels of sensory photobeams; one
level elevated 3 cm from the ﬂoor of the arena and the other 14 cm,
measuring horizontal and vertical activity respectively. Each level
of the detection systemwas equipped with 16 photobeams per wall
of the arena, spaced 2.5 cm apart. The parameters measured by the
system were: ambulatory horizontal distance moved (cm), rearing
frequency and rearing time (s). Prior to testing, all rats were
habituated in an annexe to the testing room.
Statistical analysis
All statistical processing was performed in GraphPad Prism
version 6.0 (San Diego, CA, USA). For all analyses P < 0.05 was
Fig. 1. Effect of MIA on burrowing behavior. (A) Amount of sand burrowed by naïve
rats and 3 days after intra-articular (i.a.) of saline or MIA (3 mg/knee). Rats either
received unilateral (right knee) or bilateral injections of saline/MIA. Data analyzed with
1-way ANOVA followed by Bonferroni's post hoc multiple comparisons (****P < 0.0001
vs sham bilateral group, n ¼ 12 per group). (B) Concentration-response to bilateral i.a.
injections of MIA 3 days after injection. Data analyzed with 1-way ANOVA followed by
Bonferroni's post hoc multiple comparisons (*P < 0.05 and **P < 0.01 vs sham group,
n ¼ 10e11 per group). (C) Time-course of burrowing performance after unilateral and
bilateral i.a. MIA injections (3 mg/knee). Data were analyzed with 2-way repeated
measures ANOVA (MIA  time interaction: F4,48 ¼ 12.93, P < 0.0001), followed by
Bonferroni's post hoc multiple comparisons (signiﬁcant differences compared with
sham group on same day: **P < 0.01,****P < 0.0001, n ¼ 12 per group). BL ¼ baseline.
L.A. Bryden et al. / Osteoarthritis and Cartilage 23 (2015) 1605e1612 1607considered statistically signiﬁcant. To control for familywise type I
error rates a Bonferroni correction was applied where appropriate.
A 1-way analysis of variance (ANOVA) with Bonferroni's post hoc
was used to analyze the model conditions studies investigating
whether uni- or bilateral MIA injections weremost appropriate and
the concentration-dependency of burrowing deﬁcits. A Bonferroni
cut-off of P < 0.025 was applied: 0.05/(number of comparisons per
family (2)/number of families(1)). The time-course study was
analyzed using 2-way repeated measures ANOVA. Signiﬁcant dif-
ferences between sham animals and MIA-injected animals on the
same day were ascertained using Bonferroni's post hoc. A Bonfer-
roni cut-off of P < 0.025 was applied: 0.05/(number of comparisons
per family (4)/number of families(2)). The statistical signiﬁcance of
deﬁcits in locomotor activity parameters was analyzed using an
unpaired Student's t test.
For all pharmacology studies (burrowing and locomotor activ-
ity) data were analyzed using a 2-way ANOVA. To determine that
the MIA vehicle group was signiﬁcantly lower than the sham
vehicle group and to determine which doses of compound were
efﬁcacious in reversing burrowing deﬁcits a Dunnett's post hoc
multiple comparisons was used, comparing with the MIA vehicle
control group. All data are expressed as means and corresponding
95% conﬁdence intervals (CI). Gaussian distribution was analyzed
using a ShapiroeWilk normality test.
Results
Establishment of model conditions
To determine whether unilateral or bilateral MIA injections
were most appropriate for the burrowing assay an experiment was
conducted for comparison. Injection of MIA bilaterally resulted in a
60% reduction in burrowing performance compared with the sham
bilateral control group 3 days post-injection, whereas unilaterally
MIA-injected rats displayed no deﬁcit in burrowing performance at
day 3 [Fig. 1(A)], or at later time points of 14, 21 and 28 days
[Fig. 1(C)]. We investigated the effect of saline sham injections on
burrowing performance and found that neither unilateral nor
bilateral injections of saline inﬂuenced burrowing behavior
[Fig. 1(A)]. Next we wanted to establish the concentration-
responsiveness of MIA-induced burrowing deﬁcits. Concentra-
tions of 0.3, 1 and 3 mg/knee were selected based on previous
ﬁndings in WB6. The 0.3 mg/knee concentration of MIA did not
signiﬁcantly impair burrowing performance, whereas 1 and 3 mg/
knee induced signiﬁcant deﬁcits [Fig. 1(B)]. Although 1 and 3 mg/
knee concentrations produced comparable deﬁcits, we decided on
3 mg/knee for pharmacological experiments as this concentration
produced the most robust deﬁcit with the least variance.
To establish time points for pharmacological experiments bur-
rowing performance was assessed 3, 14, 21 and 28 days after the
bilateral injection of MIA [Fig. 1(C)]. As seen in [Fig. 1(C)], a robust
deﬁcit occurred at 3 days post-injection, which resolved back to
baseline values by the 14 day time point. However, the deﬁcits at
the 21 and 28 day time points in the pharmacology experiments
were found not to be large enough to provide an assay window to
titrate a reversal effect. Therefore, it was decided to focus on the 3
day time point for all pharmacology.
After establishing the model conditions for the burrowing assay,
the same conditions were chosen for locomotor activity studies to
allow for comparisons between these two assays. Three days after
bilateral injection of MIA (3 mg/knee) deﬁcits in distance moved
[Fig. 2(A)], rearing frequency [Fig. 2(B)] and rearing time [Fig. 2(C)]
occurred. We decided to use rearing frequency as the parameter for
pharmacology studies as it had the largest deﬁcit; rearing frequency
was 48% lower in MIA injected animals than in sham animals.Rearing time was similarly reduced by MIA injection, whereas the
deﬁcit in distance moved was more modest (21% lower than sham
group). At day 28 there was no statistically signiﬁcant effect of MIA
on any locomotor activity parameter (Supplementary Table 2).
Effect of NSAIDs, morphine and gabapentin on deﬁcits in burrowing
performance
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) and opioids are
categories of drugs that are currently used to treat pain in OA
Fig. 2. Locomotor activity 3 days after bilateral injection of saline or 3 mg/knee MIA.
Distance moved (A), rearing frequency (B) and rearing time (C) was monitored over a
30 min period. Data were analyzed with unpaired Student's t test (*P < 0.05 vs sham
group, n ¼ 8 per group).
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deﬁcits in burrowing performance 3 days after the injection of MIA.
Both the non-selective cyclooxygenase (COX) inhibitor ibuprofen
and the COX-2 selective inhibitor celecoxib were efﬁcacious in
reinstating deﬁcits in burrowing performance at doses of 10 and
30 mg/kg for ibuprofen, and 3, 10 and 30 mg/kg for celecoxib
[Fig. 3(A) and (B), respectively]. The increase in burrowing perfor-
mance elicited by ibuprofen and celecoxib at these doses was a
minimum of 50% when compared with the MIA vehicle group.
Neither morphine or gabapentin reversed burrowing deﬁcits at
any dose tested [Fig. 3(C) and (D)], and morphine impaired bur-
rowing performance at 3 mg/kg in the sham group.Effect of an anti-NGF mAb and the FAAH inhibitor PF-04457845 on
deﬁcits in burrowing performance
An anti-NGF mAb was tested in the burrowing in light of recent
phase III clinical trials with an antibody of the same mechanism of
action31. When given 24 h before measurement of burrowing per-
formance the antibody had no effect on sham animals and was able
to reverse the deﬁcit in burrowing behavior induced by MIA to a
level similar to that of the respective sham group, at a dose of 9 mg/
kg [Fig. 4(A)].
The FAAH inhibitor PF-04457845 is another analgesic with a
novel mechanism of action tested in burrowing because of recent
negative phase II clinical trials in patients with knee OA32. At all
doses tested (10, 30 and 100 mg/kg) there was no reversal of bur-
rowing deﬁcits observed in MIA injected rats and also no effect on
burrowing performance in the sham animals [Fig. 4(B)].
Locomotor activity pharmacology
Supplementary Table 1 shows that in our hands no analgesic
effect of any drugs tested was detectable in the rearing frequency
parameter of the locomotor activity assay, which is in contrast to
the pharmacological sensitivity evident in the burrowing assay. The
10 mg/kg dose of morphine caused a signiﬁcant reduction in rear-
ing frequency compared with the sham vehicle group; however,
unlike for burrowing, there was no signiﬁcant reduction in rearing
frequency induced by the 3 mg/kg dose (P ¼ 0.18) compared with
sham vehicle.
Discussion
The initial aim of this study was to investigate whether bur-
rowing was impaired by i.a. injection of MIA and could therefore
provide a measure of pain-related behavior in this pre-clinical
model of OA. Our model conditions studies showed that injecting
MIA into only one knee joint was insufﬁcient to cause depression of
burrowing behavior, however, bilateral injection resulted in a
robust deﬁcit in performance. One possibility for this is that when
MIA injections are given unilaterally compensation occurs through
use of the three unaffected limbs to burrow.
In contrast, previous studies investigating the effect of intra-
plantar (i.pl) complete Freund's adjuvant (CFA), i.a. CFA and nerve
ligation models of neuropathic pain found unilateral injury to be
sufﬁcient to depress burrowing behavior16,18,19,24. It could be
inferred that the MIAmodel is less severe in its pain phenotype and
effect on animal well-being, therefore bilateral injury is needed to
induce a deﬁcit. However, unilateral injection of MIA is sufﬁcient to
induce deﬁcits in wheel-running33 and locomotor activity34 in rats,
perhaps suggesting burrowing is less sensitive to MIA-induced
joint pain than these assays. Depression of locomotor activity
after unilateral MIA injectione shown byMore et al. (2013)34e is in
contrast to studies in our laboratory where no deﬁcit occurred at
the early (day 3) or late (day 28) time points (data not shown). The
temporal pattern of MIA-induced deﬁcits in burrowing perfor-
mance was biphasic, which is similar to reported ﬁndings in WB6
and biotelemetric assessment of mobility (BAM)27.
It has been suggested from behavioral and histological ﬁndings
that the early phase of the MIA model (day 3 in our study) is
predominantly pain mediated by inﬂammation6,7, whereas the
later stages of the model represent pain of a different aetiology,
perhaps neuropathic in nature35. This is inferred from observed
upregulation of nerve injury markers at the late phase time
points36e38 and sensitivity to drugs used to treat neuropathic
pain37. However, it is important to point out that previous studies
mentioned here used unilateral MIA injections, whereas we
Fig. 3. The effect of NSAIDs, morphine and gabapentin on burrowing performance 3 days after bilateral 3 mg/knee MIA or sham injections. Data analyzed with 2-Way ANOVA
followed by Dunnett's post hoc multiple comparisons. (A) Ibuprofen (p.o.) administered 2 h before burrowing performance was measured (MIA  dose interaction: F3,66 ¼ 2.785,
P < 0.05; ##P < 0.01 vs sham vehicle, *P < 0.05, **P < 0.01 vs MIA vehicle). N ¼ 9e10 per group. (B) Celecoxib (p.o.) administered 2 h before burrowing performance was measured
(MIA  dose interaction: F3,68 ¼ 2.82, P < 0.05; ####P < 0.0001 vs sham vehicle, *P < 0.05,**P < 0.01 vs MIA vehicle). N ¼ 8e11 per group. (C) Morphine (s.c.) administered 1 h
before burrowing performance was measured (#P < 0.05, ##P < 0.01 vs sham vehicle). N ¼ 8e9 per group. (D) Gabapentin (p.o.) administered 2 h before burrowing performance
was measured (main effect of MIA: F1,62 ¼ 48.21, ****P < 0.0001). N ¼ 8e9 per group.
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unilateral and bilateral injections should therefore be borne in
mind. Taking this into account we suggest that the early phase
deﬁcits in burrowing represent inﬂammatory pain, which resolves
by day 14 and a return of deﬁcits in the late phase could be chronic/
neuropathic in nature. We tested the neuropathic pain drug
gabapentin at day 3 but found no effect at any dose tested, which is
supportive of primarily inﬂammatory pain in the early phase of the
MIA model. Unfortunately, the assay window for pharmacology at
day 21 and 28 was found to be insufﬁcient, therefore it was not
possible to use gabapentin to discern whether this late phase was
neuropathic in nature. It was estimated that 20e25 rats per
treatment group would be required to determine a pharmaco-
logical effect at day 28.
These characterization studies show that deﬁcits in burrowing
behavior can be used as an objective measure of pain-related
behavior in the MIA model of OA. Burrowing is a self-rewarding
behavior39 that is not appetite-driven and is indicative of animal
well-being17. It is suggested that burrowing is able to measure the
negative impact of pain on motivation (affective aspect) in addition
to pain evoked by the act of burrowing (sensory aspect). Recent
reviews have highlighted the need to assess the global impact of
pain in preclinical models of pain beyond measures of hypersen-
sitivity9,10,12,13 through use of more ethological rodent behaviors25.
Burrowing may provide one means of achieving this. However,
further characterization in rodent models is needed to disinter
what aspects of pain burrowing measures compared with other
assays and whether results from burrowing can be differentially
interpreted.
To investigate whether MIA-induced deﬁcits in burrowing per-
formance were sensitive to reversal by analgesics we tested a range
of compounds that work by mechanisms of action currently used totreat pain associated with OA clinically5. Both the non-selective COX
inhibitor ibuprofen and the COX-2 selective inhibitor celecoxib (375-
fold selectivity for COX-240) were efﬁcacious in reversing deﬁcits in
burrowing performance at lowdoses of 10 and 3mg/kg, respectively.
Similarly, previous published ﬁndings found that a relatively low
dose of ibuprofen (30 mg/kg) was efﬁcacious in reversing deﬁcits in
burrowing induced by i.pl CFA16. Both our study and this previous
work demonstrate that burrowingmay have higher sensitivity to the
analgesic effect of ibuprofen than evoked endpoints. In the carra-
geenan model of inﬂammatory pain the minimally effective dose
(MED) of ibuprofen to reverse mechanical allodynia was 300 mg/kg
and to reverse thermal hyperalgesia 1000 mg/kg41, which is
considerably higher than the MED in burrowing. However, such
comparisons should be approached with caution due to the differ-
ences in the underlying neurophysiological mechanisms between
pain models and the strain of rat used for experimentation.
Morphine did not signiﬁcantly reverse deﬁcits in burrowing
performance at any dose tested, and 3 mg/kg caused a signiﬁcant
reduction in burrowing performance in sham animals, presumably
due to sedative side effects. This is in contrast to a previous pub-
lished study which showed morphine to be efﬁcacious in reversing
burrowing deﬁcits induced by i.a. CFA at 1 and 3.16 mg/kg, without
reduction in burrowing performance in naïve rats19. However, the
route of administration used was intraperitoneal (i.p.) in this pre-
vious study, whereas in this study morphine was administered s.c.
The sedative side effects of morphine at 3 mg/kg was reﬂected in
previous sLA experiments28 and in our sLA studies signiﬁcant
reduction in rearing frequency occurred at 10 mg/kg.
In WB, the efﬁcacy of morphine in normalizing deﬁcits induced
by MIA is observed at 3 mg/kg8,42 e a dose which caused a
reduction in burrowing performance e and reversal of mechanical
hyperalgesia occurs at 6 mg/kg7. There is the possibility of false
Fig. 4. The effect of the anti-NGF mAb and the FAAH inhibitor PF-04457845 on bur-
rowing performance 3 days after bilateral 3 mg/knee MIA or sham injections. Data
analyzed with 2-Way ANOVA followed by Dunnett's post hocmultiple comparisons. (A)
anti-NGF mAb administered 24 h before burrowing performance was measured
(MIA  dose interaction: F1,28 ¼ 7.273, P < 0.05; ###P < 0.001 vs sham vehicle,
**P < 0.01 vs MIA vehicle). N ¼ 8 per group. (B) PF-04457845 (p.o.) administered 2 h
before burrowing performance was measured (main effect of MIA: F1,65 ¼ 54.65,
****P < 0.0001). N ¼ 8e10 per group.
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may impair motor function and tone. This impairment could cause
a shift in weight onto the ipsilateral injected knee when WB is
measured, in addition to any analgesia-mediated effect, and may
also inhibit withdrawal reﬂexes. This highlights an advantage of
assays that rely on the reinstatement of pain-depressed behaviors
by analgesics: there is no risk of detecting false positives when
drugs that potentially impair motor functioning are tested25.
The anti-NGF mAb tanezumab has been shown to be efﬁcacious
in phase III clinical trials for OA pain, improving pain scores
(including global pain assessment) and physical functioning32. In
our study an anti-NGFmAbwith the samemechanism of actionwas
effective in reversing deﬁcits in burrowing performance in the MIA
model. This further demonstrates the predictive validity of the
burrowing assay.
PF-04457845, a FAAH inhibitor, showed no efﬁcacy at any dose
tested in burrowing or sLA assays. Although no published data
demonstrating an effect of this compound at the 3 day time point in
the MIA model are available there is data showing a positive effect
in ameliorating mechanical hyperalgesia in the i.pl CFA model of
inﬂammatory pain, and at the 14 day time point in the MIA
model43. However, results from a clinical trial with PF-04457845
failed to show effective analgesia despite raised levels of endo-
cannabinoids32 indicative of FAAH inhibition. The authors suggest a
lack of translation between animal models and clinical data in light
of the studies showing a potent effect of the compound preclini-
cally. Whether this lack of translation is a result of a fault in theassessment of pain in preclinical models is not ascertainable at this
stage. Parallel studies investigating both spontaneous and evoked
endpoints in the MIA model would allow for more comprehensive
comparisons.
In contrast to burrowing, no analgesic effect of any drug was
observed in sLA. Previous pharmacological characterization of MIA-
induced deﬁcits in rearing frequency demonstrated an acute anal-
gesic effect of analgesics such as celecoxib and morphine29. In our
hands, reversal of burrowing deﬁcits provides a more sensitive
read-out for analgesic drug effect, which is in line with the ﬁndings
comparing i.a. CFA-induced burrowing deﬁcits and locomotor ac-
tivity18. Furthermore, deﬁcits in burrowing performance are inde-
pendent of motor impairment, as measured by the locomotor
activity assay; we found no correlation between burrowing
behavior or any locomotor activity parameters 3 days after i.a. MIA
injections (data not shown).
The rationale behind the development of nonreﬂexive and
ethologically relevant behavioral paradigms is to improve trans-
lation of preclinical to clinical ﬁndings. To complement this, the
underlying pathophysiology of the animal model used should be as
close to the human condition as possible. In that regard, the late
phase (28 day time point) of the MIA model is perhaps more
translational as it is suggested to model the chronic, noninﬂam-
matory pain that is more relevant to OAwhen it presents clinically.
However, it must be noted that denotating OA as ‘noninﬂammatory’
may refer to a subset of patients, as there is evidence for inﬂam-
matory markers in some cases44. This highlights the complexity
and heterogeneity of OA as a disease. Nevertheless, further studies
are warranted to optimize the burrowing paradigm to enable
pharmacological testing at the 28 day time point.
In conclusion, these data demonstrate that burrowing provides
an objective read-out for pain in the early phase of the MIA model
and is sensitive to reversal by NSAIDs and an anti-NGFmAb. As well
as having the advantage of being objective, the lack of experimenter
presence during the test period in the burrowing assay reduces the
inﬂuence of stress on rodent behavior. This is illustrated by a recent
study showing that rodent pain responses are inhibited by the
presence of a male experimenter due to stress-induced by axillary
secretions45. We also found that burrowing has superior sensitivity
to pharmacological modulation over sLA, which is in line with
ﬁndings in the i.a. CFA model of rheumatoid arthritis19, further
supporting the utility of burrowing as a preclinical pain assay.
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